Dilek Caglayan
Konya, 42080, Turkey
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.
Journal: Medicina (Kaunas, Lithuania)
Published: June 04, 2026
Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: February 19, 2026
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study.
Journal: Journal of chemotherapy (Florence, Italy)
Published: December 19, 2025
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.
Journal: Medicina (Kaunas, Lithuania)
Published: November 24, 2025
Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab.
Journal: Journal of inflammation research
Published: June 12, 2025
Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma.
Journal: Seminars in thoracic and cardiovascular surgery
Published: May 04, 2025
Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Journal: Scientific reports
Published: March 19, 2025
The impact of body mass index on the progression-free survival of CDK 4/6 inhibitors in metastatic breast cancer patients.
Journal: Future oncology (London, England)
Published: September 24, 2024
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.
Journal: Journal of chemotherapy (Florence, Italy)
Published: June 21, 2024
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Journal: Expert opinion on pharmacotherapy
Published: April 03, 2024
Last Updated: 09/26/2026